Corcept Therapeutics ((CORT)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Corcept Therapeutics is conducting a study titled ‘Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM).’ The primary objective is to assess the prevalence of endogenous hypercortisolism (eHC) in patients with resistant hypertension (rHTN). This study is significant as it could provide insights into the underlying causes of rHTN, potentially leading to better treatment strategies.
The study is non-interventional, meaning it does not involve any active treatment or intervention. Instead, it focuses on observing and collecting data from participants to understand the prevalence of eHC in the target population.
The study design is observational with a cohort model and a cross-sectional time perspective. It involves multiple visits for screening, blood tests, and potentially a CT scan for those diagnosed with eHC. There is no allocation or masking involved as it is purely observational.
The study began on March 28, 2025, with an estimated completion date not yet specified. The latest update was submitted on July 7, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
This study could have significant market implications for Corcept Therapeutics, potentially influencing their stock performance. Positive findings might boost investor confidence, especially if the study uncovers new treatment avenues for rHTN. Competitors in the hypertension treatment market will likely monitor these developments closely.
The study is currently ongoing, with further details available on the ClinicalTrials portal.